NUGC-4 Xenograft Model Service for Gastric Cancer

The NUGC-4 xenograft model represents a well-characterized preclinical platform for evaluating therapeutic strategies against gastric signet-ring cell carcinoma, offering researchers a reliable system to study tumor progression and drug response in vivo. Alfa Cytology provides comprehensive NUGC-4 xenograft model services, leveraging rigorous quality control and standardized protocols to support your preclinical gastric cancer research programs with reproducible, publication-ready data.

Overview of NUGC-4 Xenograft Model for Gastric Cancer

The NUGC-4 cell line was established from a metastatic paragastric lymph node of a 35-year-old female patient diagnosed with poorly differentiated adenocarcinoma exhibiting focal signet-ring cell carcinoma features. In vitro, NUGC-4 cells display predominantly spherical morphology with epithelial characteristics confirmed by electron microscopy, including well-developed endoplasmic reticulum, Golgi apparatus, cytoplasmic filaments, and desmosome-like junctions. The cells exhibit a near-triploid karyotype with a modal chromosome number of 52-54 in vitro and approximately 53 in vivo, with a doubling time of approximately 29.9 to 36 hours under standard culture conditions. Notably, NUGC-4 demonstrates the highest in vitro sensitivity to anticancer agents such as mitomycin C and adriamycin among the NUGC series, indicating a distinct drug-responsive profile.

When implanted into immunodeficient hosts, NUGC-4 xenografts maintain histological fidelity to the parent tumor, displaying a scirrhous carcinoma pattern characteristic of diffuse-type gastric cancer. The model has been validated across multiple preclinical applications, including peritoneal metastasis studies, drug response profiling, and molecular characterization of the EGFR/amphiregulin/HB-EGF and CXCR4/CXCL12 signaling axes. NUGC-4 xenografts support both subcutaneous and orthotopic implantation strategies, enabling flexible study designs for evaluating novel therapeutics, combination regimens, and biomarker-driven treatment approaches in gastric cancer research.

Figure 1. Cytopathic effect of Ad-p53 and OBP-702 against human diffuse-type GC cells. (Hori, Naoto, et al., 2023)

Cell Line Information: NUGC-4

NUGC-4 (also designated as NU-GC-4, Nagoya University-Gastric Cancer-4) is a human gastric cancer cell line established from metastatic paragastric lymph node tissue obtained during surgical resection. The following table summarizes the comprehensive cell line characteristics:

Our Services

Alfa Cytology offers end-to-end NUGC-4 xenograft model services tailored to your preclinical research objectives, from cell line authentication and tumor implantation through endpoint analysis and data reporting. Our team ensures rigorous quality control at every stage, delivering reproducible tumor models that meet the standards required for drug efficacy studies, biomarker validation, and mechanistic investigations in gastric cancer.

Workflow of NUGC-4 Xenograft Model Construction

The construction of NUGC-4 xenograft models follows a standardized, multi-step workflow designed to ensure tumor engraftment consistency, animal welfare compliance, and data integrity. Each phase is executed under strict quality control measures to support reliable preclinical outcomes.

1. Step 1: Cell Line Preparation and Authentication --- NUGC-4 cells are expanded under standardized culture conditions (RPMI 1640 + 10% FBS, 37 degrees C, 5% CO2) and authenticated via STR profiling prior to implantation. Mycoplasma screening is performed to confirm culture purity, and cells are harvested at optimal confluency for maximum viability.
2. Step 2: Host Selection and Acclimation --- Immunodeficient mice (e.g., nude mice or NOD/SCID) are selected based on study design requirements and acclimated for a minimum of one week under controlled environmental conditions. Health status is verified before tumor cell inoculation.
3. Step 3: Tumor Cell Inoculation --- NUGC-4 cells are prepared as a cell suspension in PBS or Matrigel at a concentration of 1.0 x 10^6 cells per 100-200 microL. The cell suspension is injected subcutaneously into the flank or orthotopically into the gastric wall, depending on the experimental objective.
4. Step 4: Tumor Monitoring and Growth Assessment --- Tumor development is monitored through regular caliper measurements beginning approximately 7-10 days post-implantation. Tumor volume is calculated using the formula (length x width^2) / 2. Body weight and general health status are recorded to ensure animal welfare compliance.
5. Step 5: Study Intervention and Endpoint Analysis --- Upon reaching a predetermined tumor volume (typically 100-200 mm^3), animals are randomized into treatment groups. Test compounds are administered according to the study protocol, with tumor measurements and body weight monitoring performed at defined intervals. At study termination, tumors are excised, weighed, and processed for histological, molecular, or pharmacodynamic analysis.
6. Step 6: Data Compilation and Reporting --- All experimental data, including tumor growth curves, body weight changes, and histopathological findings, are compiled into a comprehensive study report. Statistical analysis is performed to evaluate treatment efficacy, and raw data is archived for future reference or regulatory submissions.

Figure 2: Schematic workflow illustrating the derivation and construction of the NUGC-4 Xenograft Model at Alfa Cytology.

Case Study-NUGC-4 Xenograft Model Development

In a representative preclinical study, NUGC-4 cells were successfully engrafted into immunodeficient mice to establish a subcutaneous xenograft model for evaluating novel therapeutic candidates against gastric signet-ring cell carcinoma. Tumors exhibited consistent growth kinetics with a scirrhous histological pattern mirroring the original patient tumor. Treatment arms demonstrated differential responses, with measurable changes in tumor volume, body weight stability, and histopathological markers. Molecular profiling of excised tumors confirmed maintenance of key signaling pathways, including EGFR and CXCR4 expression. This case illustrates the utility of the NUGC-4 model for generating robust preclinical efficacy data to support downstream drug development decisions. [Specific quantitative data to be inserted upon client request.]

Why Choose Alfa Cytology?

Alfa Cytology delivers specialized preclinical tumor model services with a focus on scientific rigor, operational transparency, and client collaboration. Our NUGC-4 xenograft program is designed to accelerate your gastric cancer research while maintaining the highest standards of quality and reproducibility.

• Experienced scientific team with deep expertise in gastric cancer xenograft models and preclinical study design.
• Rigorous cell line authentication via STR profiling and routine mycoplasma screening to ensure model integrity.
• Standardized protocols with documented SOPs for tumor implantation, monitoring, and endpoint analysis.
• Flexible study designs supporting subcutaneous, orthotopic, and metastatic model configurations.
• Comprehensive data packages including tumor growth curves, body weight monitoring, histopathology, and molecular analysis.
• Dedicated project management with regular progress updates and transparent communication throughout the study lifecycle.
• Compliance with institutional animal care and use committee (IACUC) guidelines and ARRIVE reporting standards.

Contact Us

Ready to advance your gastric cancer research with a validated NUGC-4 xenograft model? Please reach out to us today via our inquiry form or email to learn more about our NUGC-4 Xenograft Model services.

For research use only. Not intended for any clinical use.